Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (34)

2024

  1. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  2. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  3. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  4. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  5. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

  6. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

2023

  1. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  2. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  3. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

  4. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia(Front. Oncol., (2022), 12, (968340), 10.3389/fonc.2022.968340)

    Frontiers in Oncology

  5. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

    HemaSphere, Vol. 7, Núm. 10, pp. E961

  6. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  7. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9

  2. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  3. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

    Frontiers in Oncology, Vol. 12

  4. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  5. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  6. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014